On September 2, 2021 Sentinel Oncology reported that it has entered an agreement with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies to support the clinical development of a first-in-class therapeutic with the potential to treat Fragile X syndrome (FXS), a rare, genetic condition that causes intellectual disability, behavioral and learning challenges, and various physical characteristics (Press release, Sentinel Oncology, SEP 2, 2021, View Source [SID1234587259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to be collaborating with the MSRD team to advance SOL784 into clinical development" said Robert G Boyle, founder and CEO of Sentinel Oncology. "SOL784 targets the underlying disease biology of FXS and we are excited for the prospects of a drug which has the potential to provide real benefits to patients for whom there is an unmet medical need".